Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3082762 | 0.68 | NPC1 (0.42) | KDM4ENPC1RAB9AMAPTCYP1A2 | |
| SCHEMBL6333199 | 0.67 | KDM4E (0.36) | KDM4ENPC1RAB9AMAPTCYP1A2 | |
| SCHEMBL17028970 | 0.65 | KDM4E (0.33) | KDM4ENPC1RAB9AMAPTCYP1A2 | |
| SCHEMBL5464859 | 0.65 | KMO (0.31) | — | |
| SCHEMBL1169059 | 0.64 | KDM4E (0.34) | KDM4ENPC1RAB9AMAPTCYP1A2 | |
| SCHEMBL5035031 | 0.64 | LMNA (0.40) | NPC1RAB9AMAPTCYP1A2CYP2C9 | |
| SCHEMBL4059081 | 0.62 | CYP1A2 (0.57) | KDM4ENPC1RAB9AMAPTCYP1A2 | |
| SCHEMBL3674913 | 0.61 | KDM4E (0.33) | KDM4ENPC1RAB9AMAPTCYP1A2 | |
| SCHEMBL5930335 | 0.61 | KDM4E (0.33) | KDM4ENPC1RAB9AMAPTCYP1A2 | |
| SCHEMBL8491506 | 0.61 | KDM4E (0.39) | KDM4ENPC1RAB9AMAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2059305-A2 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | Novartis Ag (CH) | 2009-05-20 | — | — | EP | claimed |
| WO-2008014307-A2 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | NOVARTIS AG (CH) | 2008-01-31 | — | — | WO | claimed |
| US-20150329864-A1 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20050239801-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239801-A1 | Novel compounds | CHRM2, CHRM1, C1R | KDM4E 1795/4885NPC1 128/4885RAB9A 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.